Medicus Pharma Ltd. Announces Appointment of Huma Qamar, MD as Chief Scientific Officer & Head of R&D Program

Toronto, Ontario--(Newsfile Corp. - October 18, 2023) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Huma Qamar, MD as the Chief Scientific Officer & Head of R&D Program.

Dr. Qamar has worked in the clinical research field for some of the most renowned Ivy league institutions such as Yale University, Harvard University and the University of Pennsylvania. She has robust experience in developing Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, billing and compliance audits, and medical affairs team management. She has expertise in multiple therapeutic areas, including Oncology (Heme-Onc, CAR-T, rare tumors, sarcoma, melanoma, Women's health, GU & GI, fetal oncology), gene therapy, vaccines, rheumatology, dermatology, neurology, cardiology, hepatology, and infectious diseases. Dr. Qamar was most recently serving as the Head of Clinical Development & Clinical Operations at Ocugen Inc.

"We are thrilled to welcome Dr. Qamar to lead our R&D program," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Huma is a trusted and a respected leader in the industry, well-liked by her peers and superiors, and is well known for her laser sharp focus and sense of urgency to deliver measurable results in drug development."

The company also announced election of James P. Quinlan, Medicus Chief Financial Officer, as Chairman of the Board, Skinject, Inc, the wholly owned subsidiary of Medicus, along with Dr. Edward J Brennan, the Chief Medical Officer of the company, and Carolyn Bonner, the President of company, as members of the Skinject, Inc, Board of Directors.

For further information contact:

Carolyn Bonner, President
(610)636-0184
cbonner@medicuspharma.com

About Medicus Pharma Ltd:

Medicus Pharma Ltd. (TSXV: MDCX) is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

Through our diverse experience and extensive industry network, we are building Medicus into a leading pharmaceutical holding company, committed to delivering better treatment outcomes and alleviate pain and suffering. Utilizing a thesis driven collaborative process, we identify, acquire and advance relatively de-risked clinical stage assets through clinical development and commercialization.

Skinject Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell and squamous cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The company currently has an FDA approved phase 2 trial actively recruiting patients.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes future-oriented financial information with respect to prospective financial performance, financial position or cash flows that is presented as a forecast or a projection. Forward-looking statements are often but not always, identified by the use of such terms as "may", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on SEDAR+, which may impact, among other things, the Company's ability to advance SkinJect's R&D programs, and potentially identify and invest in additional bio-technology targets. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Readers are cautioned that the foregoing list is not exhaustive and readers are encouraged to review the Prospectus accessible on the Company's profile on SEDAR+ at www.sedarplus.ca. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/184346